Pituitary-Dependent Cushing's Disease

Categories: Endocrine diseases

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

MalaCards integrated aliases for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease 12 15 73
Pituitary-Dependent Cushing Disease 12
Pituitary Acth Hypersecretion 44
Overproduction of Acth 12


External Ids:

Disease Ontology 12 DOID:3946
ICD10 33 E24.0
MeSH 44 D047748
NCIt 50 C113210
SNOMED-CT 68 9545009
UMLS 73 C0221406

Summaries for Pituitary-Dependent Cushing's Disease

MalaCards based summary : Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to acth-secreting pituitary adenoma and pituitary adenoma 4, acth-secreting. An important gene associated with Pituitary-Dependent Cushing's Disease is SST (Somatostatin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Corticotropin-releasing hormone signaling pathway. The drugs Pasireotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and ovary, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Pituitary-Dependent Cushing's Disease

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 acth-secreting pituitary adenoma 33.0 CRH POMC PRL
2 pituitary adenoma 4, acth-secreting 11.0
3 bronchus adenoma 10.3 POMC SST
4 bronchial adenomas/carcinoids childhood 10.3 POMC SST
5 acidophil adenoma 10.3 POMC SST
6 generalized resistance to thyroid hormone 10.3 PRL TRH
7 gangliocytoma 10.3 CRH POMC
8 prolactin producing pituitary tumor 10.3 PRL SST
9 pseudohypoparathyroidism, type ia 10.2 PRL TRH
10 ectopic cushing syndrome 10.2 CRH POMC SST
11 spinocerebellar degeneration 10.2 CRH PRL SST
12 suprasellar meningioma 10.2 POMC TRH
13 pituitary tumors 10.2 POMC PRL SST
14 adenohypophysitis 10.2 POMC PRL TRH
15 scleredema adultorum 10.2 INS POMC
16 acth deficiency, isolated 10.2 CRH POMC
17 sella turcica neoplasm 10.2 GHRH POMC PRL
18 glucagonoma 10.2 GHRH SST
19 hypogonadotropism 10.2 GNRH1 PRL
20 tuberculum sellae meningioma 10.2 GHRH POMC PRL
21 gigantism 10.2 GHRH PRL
22 duodenal somatostatinoma 10.2 INS SST
23 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.2 CYP21A2 POMC
24 postgastrectomy syndrome 10.2 INS SST
25 postural hypotension 10.2 INS SST
26 acute adrenal insufficiency 10.2 CYP21A2 POMC
27 melancholia 10.2 CRH PRL
28 cytochrome p450 oxidoreductase deficiency 10.2 CYP21A2 POMC
29 pituitary carcinoma 10.2 CRH POMC PRL SST
30 nelson syndrome 10.2 CRH POMC PRL SST
31 pancreatic endocrine carcinoma 10.2 INS POMC SST
32 adrenal cortex disease 10.2 CRH POMC PRL SST
33 burns 10.2 CRH INS
34 pylorospasm 10.2 HTR4 SST
35 hypoadrenalism 10.2 CRH POMC
36 diabetes insipidus, neurohypophyseal 10.2 GNRH1 POMC PRL
37 hypothyroidism, congenital, nongoitrous, 4 10.1 CRH POMC PRL TRH
38 pituitary adenoma, prolactin-secreting 10.1 POMC PRL SST TRH
39 pancreas disease 10.1 INS POMC SST
40 insulinomatosis and diabetes mellitus 10.1 INS SST
41 adrenal cortical hypofunction 10.1 CRH CYP21A2 POMC
42 glucose metabolism disease 10.1 INS POMC SST
43 hypoadrenocorticism, familial 10.1 CRH CYP21A2 POMC
44 adrenal gland disease 10.1 CRH POMC SERPINA6 SST
45 non-functioning pituitary adenoma 10.1 GHR SST
46 adrenal carcinoma 10.1 CRH CYP21A2 POMC
47 panic disorder 10.1 CRH GHRH POMC
48 pituitary infarct 10.1 GNRH1 POMC PRL SST
49 chiasmal syndrome 10.1 GNRH1 POMC PRL SST
50 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 10.1 CYP21A2 NNT POMC

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:

Diseases related to Pituitary-Dependent Cushing's Disease

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 APEX1 CD59 CRH CYP27A1 GHR GHRH
2 endocrine/exocrine gland MP:0005379 10.18 APEX1 CD59 CRH CYP27A1 GHR GHRH
3 growth/size/body region MP:0005378 10.15 APEX1 CRH GHR GHRH GNRH1 HSD11B1
4 behavior/neurological MP:0005386 10.13 CRH GHR HSD11B1 HTR4 INS MC3R
5 immune system MP:0005387 10.03 APEX1 CRH GHR GHRH GNRH1 HSD11B1
6 adipose tissue MP:0005375 10 CRH GHR HSD11B1 HTR4 INS MC3R
7 liver/biliary system MP:0005370 9.9 APEX1 CRH CYP27A1 GHR GHRH GNRH1
8 nervous system MP:0003631 9.73 CRH CYP27A1 GHR GHRH GNRH1 HSD11B1
9 renal/urinary system MP:0005367 9.23 CD59 CRH CYP27A1 GHR GNRH1 INS

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pasireotide Approved Phase 4,Phase 3,Phase 2 396091-73-9 9941444
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2 51110-01-1, 38916-34-6 53481605
Metformin Approved Phase 4 657-24-9 14219 4091
Zinc Approved, Investigational Phase 4 7440-66-6
Liraglutide Approved Phase 4 204656-20-2 44147092
Lactitol Investigational Phase 4 585-86-4 3871
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Insulin, Globin Zinc Phase 4
11 insulin Phase 4
protease inhibitors Phase 4
13 Sitagliptin Phosphate Phase 4
14 Incretins Phase 4
15 Hypoglycemic Agents Phase 4,Phase 2
16 Dipeptidyl-Peptidase IV Inhibitors Phase 4
17 HIV Protease Inhibitors Phase 4
Mifepristone Approved, Investigational Phase 3,Phase 2,Not Applicable 84371-65-3 55245
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-03-3
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
25 Orange Approved Phase 3
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Ketoconazole Approved, Investigational Phase 3 65277-42-1 3823 47576
28 Contraceptive Agents Phase 3,Phase 2,Not Applicable
29 Contraceptives, Oral Phase 3,Phase 2,Not Applicable
30 Contraceptives, Postcoital Phase 3,Phase 2,Not Applicable
31 Luteolytic Agents Phase 3,Phase 2,Not Applicable
32 Epinephryl borate Phase 3,Phase 2,Not Applicable
33 glucocorticoids Phase 3,Phase 2,Not Applicable
34 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2,Not Applicable
35 Cortisol succinate Phase 3,Phase 2,Not Applicable
36 beta-endorphin Phase 3,Phase 2
37 Pharmaceutical Solutions Phase 3
38 Melanocyte-Stimulating Hormones Phase 3,Phase 2
39 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
40 Dopamine agonists Phase 3,Phase 2
41 Antiparkinson Agents Phase 3,Phase 2
42 Dopamine Agents Phase 3,Phase 2
43 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
44 Radiopharmaceuticals Phase 3
45 Antineoplastic Agents, Hormonal Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2
47 Edotreotide Phase 3
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
Nicotinamide Approved, Investigational Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
4 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
6 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
8 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
10 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
11 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
13 A Study of the Efficacy and Safety of Relacorilant Recruiting NCT03697109 Phase 3 Relacorilant
14 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
15 Open-label Treatment in Cushing's Syndrome Not yet recruiting NCT03621280 Phase 3 Levoketoconazole
16 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
17 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
18 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
19 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Unknown status NCT02713776 Phase 2 Pasireotide;Placebo
20 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
21 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
22 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
23 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
24 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
25 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
26 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
27 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
28 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
29 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
30 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
31 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Not yet recruiting NCT03708900 Phase 2 LCI699
32 Treatment of Cushing's Disease With R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
33 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
34 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
35 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
36 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
37 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
38 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
39 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Unknown status NCT02603653 Not Applicable
40 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
41 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Unknown status NCT02810496 Not Applicable
42 Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. Unknown status NCT02651844 Not Applicable Mifepristone
43 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
44 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
45 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
46 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Completed NCT01459237 Early Phase 1 Acthrel
47 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453
48 Examination of Brain Serotonin Receptors in Patients With Mood Disorders Completed NCT00026832
49 Rhinological Outcomes in Endonasal Pituitary Surgery Completed NCT01504399
50 Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness Completed NCT01613001

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Genetic Tests for Pituitary-Dependent Cushing's Disease

Anatomical Context for Pituitary-Dependent Cushing's Disease

MalaCards organs/tissues related to Pituitary-Dependent Cushing's Disease:

Pituitary, Colon, Ovary, Pancreas, Thyroid, Cortex, Adrenal Gland

Publications for Pituitary-Dependent Cushing's Disease

Articles related to Pituitary-Dependent Cushing's Disease:

(show all 14)
# Title Authors Year
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. ( 18957506 )
Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease. ( 9150699 )
Risk factors and long-term outcome in pituitary-dependent Cushing's disease. ( 8675592 )
Failure of hypophysectomy to correct pituitary-dependent Cushing's disease in two patients. ( 3190383 )
Corticotrophin-releasing factor-test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease. ( 2820618 )
A case of pituitary dependent Cushing's disease with clinical and biochemical features of the ectopic ACTH syndrome. ( 2985302 )
Is it possible to diagnose pituitary-dependent Cushing's disease? ( 3000267 )
Sodium valproate and metyrapone for pituitary-dependent Cushing's disease. ( 6147673 )
Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease. ( 6308029 )
Simultaneous bilateral venous sampling for adrenocorticotropin in pituitary-dependent cushing's disease: evidence for lateralization of pituitary venous drainage. ( 6311861 )
Pituitary-dependent Cushing disease and primary adrenocortical nodular dysplasia in childhood. Presentation of 4 cases. ( 6662137 )
Remission of pituitary-dependent Cushing's disease after removal of nonneoplastyic pituitary gland. ( 6252859 )
Pituitary-dependent Cushing's disease. ( 858043 )
Pituitary-dependent Cushing's disease. ( 193608 )

Variations for Pituitary-Dependent Cushing's Disease

Expression for Pituitary-Dependent Cushing's Disease

Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.

Pathways for Pituitary-Dependent Cushing's Disease

GO Terms for Pituitary-Dependent Cushing's Disease

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 CD59 CRH GHR GHRH GNRH1 INS
2 perikaryon GO:0043204 9.5 CRH GHRH GNRH1
3 extracellular region GO:0005576 9.36 CD59 CRH GHR GHRH GNRH1 INS
4 secretory granule GO:0030141 9.33 POMC PRL TRH
5 endosome lumen GO:0031904 9.26 INS PRL

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.84 APEX1 CRH PRL SST
2 G protein-coupled receptor signaling pathway GO:0007186 9.81 CRH GHRH GNRH1 HTR4 INS MC3R
3 response to organic cyclic compound GO:0014070 9.74 GNRH1 PRL TRH
4 steroid metabolic process GO:0008202 9.72 CRH CYP21A2 HSD11B1
5 female pregnancy GO:0007565 9.7 CRH GNRH1 PRL
6 response to ethanol GO:0045471 9.62 CRH GNRH1 PRL TRH
7 response to food GO:0032094 9.58 GHR GHRH
8 response to corticosterone GO:0051412 9.56 CRH TRH
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.51 GHR PRL
10 regulation of signaling receptor activity GO:0010469 9.5 GHRH GNRH1 INS POMC PRL SST
11 parturition GO:0007567 9.49 CRH PRL
12 ovulation cycle GO:0042698 9.48 GNRH1 PRL
13 negative regulation of feeding behavior GO:2000252 9.46 INS TRH
14 hormone-mediated apoptotic signaling pathway GO:0008628 9.43 CRH SST
15 glucocorticoid biosynthetic process GO:0006704 9.43 CRH CYP21A2 HSD11B1
16 regulation of appetite GO:0032098 9.4 HTR4 POMC
17 positive regulation of lactation GO:1903489 9.37 GHRH PRL
18 cell-cell signaling GO:0007267 9.1 GHRH GNRH1 INS POMC SST TRH

Molecular functions related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.55 APEX1 CYP21A2 CYP27A1 HSD11B1 NNT
2 hormone activity GO:0005179 9.23 CRH GHRH GNRH1 INS POMC PRL
3 steroid binding GO:0005496 9.13 CYP21A2 HSD11B1 SERPINA6

Sources for Pituitary-Dependent Cushing's Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....